Blake Borgeson - 29 Jun 2023 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Director
Signature
/s/ Jonathan Golightly, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
29 Jun 2023
Net transactions value
-$273,464
Form type
4
Filing time
27 Jul 2023, 18:30:05 UTC
Previous filing
29 Jun 2023
Next filing
13 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Gift $0 -14,000 -0.19% $0.000000 7,506,104 29 Jun 2023 Direct
transaction RXRX Class A Common Stock Sale $273,464 -18,719 -0.25% $14.61 7,487,385 25 Jul 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022.
F2 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $14.16 to $15.11 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.